Comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as 'Reactive Therapy' for Canine Atopic Dermatitis: A Randomised, Single-Blinded, Controlled Preliminary Trial.

Topical triamcinolone spray enhances lokivetmab efficacy for canine atopic dermatitis management.

This randomized, single-blinded controlled trial evaluated the efficacy and safety of combining lokivetmab with 0.015% triamcinolone acetonide (TCA) topical spray versus lokivetmab monotherapy in 20 dogs with nonseasonal atopic dermatitis. Dogs were assessed at baseline, day 14, and day 28 using CADESI-04 and CADESI-04E scoring systems and the 10-grade pruritus Visual Analog Scale. The lokivetmab-TCA combination group demonstrated significant reductions in CADESI-04 and CADESI-04E scores at both day 14 and day 28 compared to baseline, while the monotherapy group showed no significant lesional improvements. By day 28, the combination therapy significantly reduced erythema compared to monotherapy. Both groups showed significant pruritus reduction at days 14 and 28. Laboratory parameters remained stable in both groups. The authors conclude that adjunctive topical TCA spray represents a safe and potentially useful addition to systemic lokivetmab therapy for managing canine atopic dermatitis, particularly in the initial treatment phase.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.